mazindol has been researched along with Muscular Dystrophy in 11 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A simple-blind therapeutic trial of mazindol (2 mg/d) versus placebo in 14 boys with Duchenne muscular dystrophy, 5 to 13 years old, for 12 months was conducted in order to analyse the efficacy of this drug on the natural history of the disease." | 9.06 | [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children]. ( Desnuelle, C; N'guyen, VK; Pinsard, N; Richelme, C; Serratrice, G, 1989) |
| "Nine children with Duchenne muscular dystrophy were given Sanorex (mazindol), a growth hormone inhibitor, daily for 6 months." | 7.67 | Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy. ( Angulo, M; Castro-Magana, M; Chen, SY; Collipp, PJ; Derenoncourt, A; Kelemen, J, 1984) |
| "Mazindol has been reported to improve muscle function in Duchenne muscular dystrophy (DMD) by virtue of its growth hormone (GH) suppression." | 7.67 | The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. ( Coakley, JH; Edwards, RH; Griffiths, RD; Hipkin, LJ; Moorcraft, J; Smith, CS, 1988) |
| "A simple-blind therapeutic trial of mazindol (2 mg/d) versus placebo in 14 boys with Duchenne muscular dystrophy, 5 to 13 years old, for 12 months was conducted in order to analyse the efficacy of this drug on the natural history of the disease." | 5.06 | [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children]. ( Desnuelle, C; N'guyen, VK; Pinsard, N; Richelme, C; Serratrice, G, 1989) |
| "A controlled, double-blind therapeutic trial with the drug mazindol, a growth hormone inhibitor, was performed in a pair of 7 1/2 year-old monozygotic twins, with Duchenne muscular dystrophy (DMD)." | 5.06 | Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. ( Betti, RT; Frota-Pessoa, O; Zatz, M, 1986) |
| "Nine children with Duchenne muscular dystrophy were given Sanorex (mazindol), a growth hormone inhibitor, daily for 6 months." | 3.67 | Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy. ( Angulo, M; Castro-Magana, M; Chen, SY; Collipp, PJ; Derenoncourt, A; Kelemen, J, 1984) |
| "Mazindol has been reported to improve muscle function in Duchenne muscular dystrophy (DMD) by virtue of its growth hormone (GH) suppression." | 3.67 | The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. ( Coakley, JH; Edwards, RH; Griffiths, RD; Hipkin, LJ; Moorcraft, J; Smith, CS, 1988) |
| " Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients." | 2.67 | Randomized, double-blind trial of mazindol in Duchenne dystrophy. ( Brooke, MH; Fenichel, GM; Florence, J; Griggs, RC; Kaiser, KK; Mandel, S; Mendell, JR; Miller, PJ; Moxley, RT; Schierbecker, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collipp, PJ | 1 |
| Kelemen, J | 1 |
| Chen, SY | 1 |
| Castro-Magana, M | 1 |
| Angulo, M | 1 |
| Derenoncourt, A | 1 |
| Griggs, RC | 1 |
| Moxley, RT | 1 |
| Mendell, JR | 1 |
| Fenichel, GM | 1 |
| Brooke, MH | 1 |
| Miller, PJ | 1 |
| Mandel, S | 1 |
| Florence, J | 1 |
| Schierbecker, J | 1 |
| Kaiser, KK | 1 |
| Zatz, M | 4 |
| Rapaport, D | 3 |
| Pavanello, RC | 1 |
| Rocha, JM | 2 |
| Vainzof, M | 3 |
| Nicolau, W | 1 |
| Desnuelle, C | 2 |
| Serratrice, G | 2 |
| N'guyen, VK | 1 |
| Richelme, C | 1 |
| Pinsard, N | 1 |
| Coakley, JH | 3 |
| Griffiths, RD | 2 |
| Edwards, RH | 3 |
| Moorcraft, J | 2 |
| Hipkin, LJ | 2 |
| Smith, CS | 2 |
| Pavanello, Rde C | 2 |
| Betti, RT | 3 |
| Otto, PA | 1 |
| da Rocha, JM | 1 |
| Frota-Pessoa, O | 1 |
6 trials available for mazindol and Muscular Dystrophy
| Article | Year |
|---|---|
Randomized, double-blind trial of mazindol in Duchenne dystrophy.
Topics: Behavior; Double-Blind Method; Feeding and Eating Disorders; Humans; Male; Mazindol; Muscle Contract | 1990 |
[A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Creatine Kinase; Drug Evaluation; Fol | 1989 |
Mazindol in Duchenne muscular dystrophy.
Topics: Child; Clinical Trials as Topic; Heart Rate; Humans; Indoles; Male; Mazindol; Muscular Dystrophies | 1988 |
[Effect of a growth hormone inhibitor on the course of Duchenne's myopathy].
Topics: Child; Growth Inhibitors; Humans; Indoles; Mazindol; Muscular Dystrophies; Time Factors | 1988 |
Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.
Topics: Child; Clinical Trials as Topic; Double-Blind Method; Growth Hormone; Humans; Indoles; Male; Mazindo | 1987 |
Treatment of Duchenne muscular dystrophy with growth hormone inhibitors.
Topics: Body Height; Body Weight; Child; Clinical Trials as Topic; Diseases in Twins; Double-Blind Method; G | 1986 |
5 other studies available for mazindol and Muscular Dystrophy
| Article | Year |
|---|---|
Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy.
Topics: Adolescent; Body Height; Body Weight; Child; Child, Preschool; Growth Disorders; Growth Hormone; Hai | 1984 |
Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine.
Topics: Adolescent; Child; Circadian Rhythm; Cyproheptadine; Growth Hormone; Humans; Indoles; Male; Mazindol | 1989 |
Height and clinical course of Duchenne muscular dystrophy.
Topics: Body Height; Data Interpretation, Statistical; Growth Hormone; Humans; Levodopa; Longitudinal Studie | 1989 |
The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
Topics: Child; Child, Preschool; Follow-Up Studies; Growth Hormone; Humans; Indoles; Male; Mazindol; Muscula | 1988 |
Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
Topics: Adolescent; Child; Child, Preschool; Growth Hormone; Humans; Indoles; Levodopa; Male; Mazindol; Musc | 1988 |